Trius Therapeutics (TSRX) Stock Research, Analysis & News
Quick Analysis on Trius Therapeutics (TSRX) Stock as of May 19, 2013
 | Previous Closing Price $7.88 is above 50 day moving average of $6.54 |
| Previous Closing Price $7.88 is above 200 day moving average of $5.53 |
 | The Stock pays no dividend |
| The closing price $7.88 is more than 60.41% away from its one year target price of $12.64 |
 | Current Short Ratio 2.60 is great than 1 |
| Earning per Share $-1.563 is negative. Trius Therapeutics is lossing money. |
| EBITDA $-61.9M is negative |
| It is a very small cap stock with market cap of $382.0M |
(See more information about Trius Therapeutics (TSRX) Stock below)
Trius Therapeutics (TSRX) Stock Profile Summary
Trius Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibiotics for serious, life-threatening infections in the United States. Its products under development include Torezolid Phosphate, which has completed phase 2 clinical trials for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus. The company is also developing antibiotics for gram-negative infections using its proprietary discovery platform under a contract funded by the National Institutes of Health. It has a cooperative research and development agreement with Lawrence Livermore National Security LLC for the research and development of gram-negative biodefense pathogens; and a license agreement with Dong-A Pharmaceutical Co., Ltd. to develop and sell Torezolid Phosphate outside of Korea. The company was formerly known as Rx3 Pharmaceuticals, Inc. and changed its name to Trius Therapeutics, Inc. in February 2007. Trius Therapeutics, Inc. was founded in 2004 and is headquartered in San Diego, California.
Trius Therapeutics (TSRX) Stock Key Statistics Research and Analysis as of May 19, 2013
| Stock Exchange | NGM |
| Market Capitalization | $382.0M
|
| Trade Volume (Average Trading Volume) | 731,868 (729,087) |
| Price/Sales | 19.77 |
| Price/Book | 5.22 |
| Earning/Share | $-1.563 |
| Current Year EPS Estimate | $-1.39 |
| Next Year EPS Estimate | $-1.24 |
| Previous Closing Price | $7.88 |
| 50 Day Price Moving Average | $6.54 |
| 200 Day Price Moving Average | $5.53 |
| 1 yr Target Price | $12.64 |
| Short Ratio | 2.60 |
| EBITDA | $-61.9M |
Trius Therapeutics (TSRX) Stock Competitor Research and Analysis
Mutual Funds with Trius Therapeutics (TSRX) Stock in its top 10 holdings
Latest Market News on Trius Therapeutics (TSRX)
Click here to find the latest news on Trius Therapeutics (TSRX)
Looking for Market Opportunties?
Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center
See other companies in the same industry
Abbott Laboratories (ABT) Pfizer Inc. (PFE)
Research on Trius Therapeutics (TSRX)
